Final frontier – 3D bioprinting in space

A strategic partnership between CELLINK and Made in Space promises advances for drug screening and cancer treatments.

CELLINK, a Swedish bioprinter manufacturer, has announced a strategic partnership with microgravity manufacturing specialist, Made in Space.

The project will see the two organisations collaborate on identifying 3D bioprinting development opportunities on the International Space Station (ISS) as well as future opportunities off-world. If successful, the project could have significant implications for drug screening and cancer research right here on Earth.

Longevity.Technology: 3D bioprinting has made great strides and the unique environment of space offers further opportunities. This is just one of a number of exciting developments that could have profound implications for healthcare back here on Earth.

The project is one of a number of initiatives to investigate the potential of 3D bioprinting in micro-gravitational environments. Earlier in the year, Russian company 3D Bioprinting Solutions sent its micro-gravitational 3D printer, the Organ Avt to the international space station which grows living tissues. Working with American and Israeli scientists, they used it to carry out experiments on printing tissues in space[1].

Another 3D bioprinter travelled to the ISS in July. The 3D biofabrication facility (BFF) aims to use adult human cells and tissue-derived proteins for viable human tissues [2].

These developments are the latest step along the path to printing human organs in space. Although this field has made considerable advances here on Earth, recreating complex structures such as capillaries has proved difficult in Earth’s gravity. The hope is that in the micro-gravity environment of the ISS, the possibilities of 3D printing could be greatly expanded.

A strategic partnership between CELLINK and Made in Space promises advances for drug screening and cancer treatments.

Indeed, space is increasingly becoming an important lab for the Longevity market.

NASA astronauts Nicky Hague and Andrew Morgan have been researching how fluid shifts caused by micro-gravity induce vascular changes and pressure in the head and eye [3]. The experiments are intended to investigate how astronauts respond to treatment in orbit and further out into space.

Amazon’s Jeff Bezos has also been pushing into the final frontier with Blue Origin which has delivered payloads for a range of scientific experimentation in what’s been termed a ‘sub orbital science extravaganza’.

As reported in Longevity.Technology Bezos has also been increasingly active in the age tech and Longevity space. He’s invested both Amazon’s and his own money in start-ups that seek to fight aging in a number of ways. For example, he invested in biotechnology start up Unity which aims to make aging as uncommon as Polio.

Space, then, is the next frontier in advanced bioprinting research. The micro-gravitational environment potentially expands the possibility of what’s achievable opening up a future in which organs can quickly and simply be bioprinted into existence. If that happens, the implications for human aging and Longevity could be profound.





Image credit: Cellink
Carla Heyworth
Carla is sub editor at Longevity.Technology and she's the glue that keeps the team on track and the articles rolling-out. She has an extensive background in B2B communications, events and marketing. Carla's a visual person and can often be found behind a camera or editing photos

Latest articles

Reproductive Longevity – taking the geroscience approach

Applying geroscience interventions to fertility pathways can promote reproductive Longevity. Dr Joon Yun is President and Managing Partner of Palo Alto Investors, LP, a hedge...

Targeting senescent cells to extend lifespan

Although our understanding of the mechanisms underlying aging is limited, recent findings from animal studies indicate that targeting cellular senescence in vivo may prevent...

At-home wellness biomarker test to deliver instant results

ZiO Health prepares to launch crowdfunding campaign for subscription-based urine test that measures multiple health biomarkers. Biomedical start-up ZiO Health is on a mission to...

Inflammaging biotech acquired by Roche for €380m

One of the largest deals in Irish biotech history sees Roche gain rights to full Inflazome portfolio. The Swiss company Roche has bought Dublin-based biotech...